image

Innovative Approaches: Key Trends in Thyroid Cancer Clinical Trials

Thyroid cancer (TC), the most common type of endocrine malignancy, has evolved rapidly in that sense with respect to development of targeted therapies and immunotherapy strategies. Differentiated thyroid cancer (DTC) has been dramatically curable with traditional treatments including surgery and radioactive iodine (RAI). Novel treatment approaches such as tyrosine kinase inhibitors and combination therapies are under investigation in clinical trials for patients with advanced radioiodine-refractory or anaplastic thyroid cancer (ATC), or medullary thyroid cancer (MTC).

Tyrosine Kinase Inhibitors (TKIs) TKIs like lenvatinib, and sorafenib have emerged as main treatment modalities for RAI-refractory thyroid cancers with significant improvement in progression-free survival (PFS) in patients with advanced DTC. In anaplastic thyroid cancer (ATC) TKIs which are targeted to the BRAF mutation have shown efficacy as well, with high response rates in clinical trials in this often chemoresistant and aggressive subset of patients​

Immunotherapy is also under investigation as a promising approach, especially with respect to the aggressive subtypes. Combined trials of checkpoint inhibitors (in this case, pembrolizumab) and TKIs (like lenvatinib) have been shown to increase response rates in metastatic and refractory thyroid cancers [7​].

In addition, the success of CAR-T cell therapy in other cancers is being investigated in advanced thyroid cancer with pre-clinical work to pave way for human trials.

Combination Therapies: These is also a key trend in therapy of aggressive thyroid cancers, ie. the combination of several agents. For example, co-targeting TKIs with MEK inhibitors, mTOR inhibitors to circumvent towards resistance mechanisms. BRAF-mutant ATCs in particular have been responsive to some of these combinations such as dabrafenib/trametinib.

Key Mechanisms of Action in Thyroid Cancer Treatment

Mechanism of Action

Key Drugs

Tyrosine Kinase Inhibition

Lenvatinib, Sorafenib, Cabozantinib

BRAF Inhibition

Dabrafenib + Trametinib

Immunotherapy (Checkpoint Inhibitors)

Pembrolizumab

mTOR Inhibition

Everolimus


Patient Population and Epidemiology

Thyroid cancer (TC), the most common type of endocrine malignancy, has evolved rapidly in that sense with respect to development of targeted therapies and immunotherapy strategies. Differentiated thyroid cancer (DTC) has been dramatically curable with traditional treatments including surgery and radioactive iodine (RAI). Novel treatment approaches such as tyrosine kinase inhibitors and combination therapies are under investigation in clinical trials for patients with advanced radioiodine-refractory or anaplastic thyroid cancer (ATC), or medullary thyroid cancer (MTC).

Tyrosine Kinase Inhibitors (TKIs) TKIs like lenvatinib, and sorafenib have emerged as main treatment modalities for RAI-refractory thyroid cancers with significant improvement in progression-free survival (PFS) in patients with advanced DTC. In anaplastic thyroid cancer (ATC) TKIs which are targeted to the BRAF mutation have shown efficacy as well, with high response rates in clinical trials in this often chemoresistant and aggressive subset of patients​

Immunotherapy is also under investigation as a promising approach, especially with respect to the aggressive subtypes. Combined trials of checkpoint inhibitors (in this case, pembrolizumab) and TKIs (like lenvatinib) have been shown to increase response rates in metastatic and refractory thyroid cancers.

In addition, the success of CAR-T cell therapy in other cancers is being investigated in advanced thyroid cancer with pre-clinical work to pave way for human trials.

Combination Therapies: These is also a key trend in therapy of aggressive thyroid cancers, ie. the combination of several agents. For example, co-targeting TKIs with MEK inhibitors, mTOR inhibitors to circumvent towards resistance mechanisms. BRAF-mutant ATCs in particular have been responsive to some of these combinations such as dabrafenib/trametinib

Expanded Table of Contents

  1. Introduction 1.1 Overview of Thyroid Cancer
    1.2 Role of Clinical Trials in Advancing Treatment

  2. Epidemiology of Thyroid Cancer
    2.1 Global Incidence and Prevalence
    2.2 Risk Factors and Demographics
    2.3 Survival and Mortality Rates

  3. Innovative Approaches in Thyroid Cancer Clinical Trials
    3.1 Advances in Targeted Therapies (TKIs, BRAF Inhibitors)
    3.2 Immunotherapy Breakthroughs
    3.3 Combination Therapies in Aggressive Cancers

  4. Mechanisms of Action in Thyroid Cancer Treatment
    4.1 Tyrosine Kinase Inhibitors
    4.2 BRAF and MEK Inhibition
    4.3 Immunotherapy (Checkpoint Blockade)
    4.4 Other Novel Approaches (mTOR Inhibition)

  5. Analysis of Ongoing Clinical Trials
    5.1 Trials for Radioiodine-Refractory DTC
    5.2 Trials Targeting Genetic Mutations (BRAF, RET, etc.)
    5.3 Trials for Anaplastic and Medullary Thyroid Cancers

  6. Patient Population and Treatment Response
    6.1 Characteristics of Patients by Cancer Type
    6.2 Response Rates by Therapy and Mutation Type
    6.3 Genetic Drivers of Treatment Response

  7. Challenges and Future Directions in Thyroid Cancer Research
    7.1 Overcoming Resistance in Advanced Disease
    7.2 Accessibility and Cost of Targeted Therapies
    7.3 Role of Biomarker-Driven Treatments

  8. Market Impact and Financial Considerations
    8.1 Growth of the Thyroid Cancer Therapeutics Market
    8.2 Economic Challenges and Global Disparities
    8.3 Future Trends in Drug Development

  9. Conclusion
    9.1 Summary of Key Findings
    9.2 Future Outlook for Thyroid Cancer Treatments

  10. Appendix
    10.1 Glossary of Terms
    10.2 Abbreviations and Acronyms
    10.3 References and Data Sources

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone